Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (HK:8329)
:8329
Want to see HK:8329 full AI Analyst Report?
8329 Stock Chart & Stats
HK$0.16
>-HK$0.01(-0.63%)
At close: 4:00 PM EST
HK$0.16
>-HK$0.01(-0.63%)
Day’s Range― - ―
52-Week RangeHK$0.11 - HK$0.21
Previous CloseN/A
Volume90.00K
Average Volume (3M)330.65K
Market Cap
HK$192.97M
Enterprise ValueHK$41.04M
Total Cash (Recent Filing)HK$209.45M
Total Debt (Recent Filing)HK$73.02M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.51%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding426,000,000
10 Day Avg. Volume371,000
30 Day Avg. Volume330,653
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow and stable leverage around 0.10–0.13 gives the company durable financial flexibility. Over the next 2–6 months this conservatism supports funding of operations, R&D or working capital needs, cushions against shocks, and lowers refinancing risk versus peers with higher debt.
Improved Cash GenerationA sharp improvement in operating cash flow and materially positive free cash flow in 2025 indicates stronger cash conversion and operational liquidity. Durable cash generation enhances ability to fund capex, service obligations and optional investments even while earnings recover.
Operational ResilienceMaintaining positive operating earnings while overall net profit turned negative suggests core operations can cover operating costs. That resilience improves the odds that margin recovery or modest revenue stabilization would restore profitability without structural overhaul.
Bears Say
Deteriorating ProfitabilitySignificant margin compression to ~29% and a 2025 net loss reduce internal funding for R&D and commercialization. Persistently weaker margins erode competitive buffer, limit pricing power, and make returns sensitive to cost or pricing shocks across the next several quarters.
Revenue Decline TrendConsecutive revenue declines weaken scale economics and suggest market-share pressure or demand softness. Continued top-line contraction would hamper margin recovery and cash generation, making it harder to regain prior profitability without clear growth initiatives.
Volatile Cash & Weakening ReturnsLarge year-to-year swings in cash flow and a decline in equity/assets in 2025 increase forecasting risk and constrain strategic choices. Falling returns and a negative ROE reduce resilience to shocks and may limit access to external capital if weakness persists.
8329 FAQ
What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.11 and its highest was HK$0.21 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$192.97M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Aug 07, 2026 which is in 78 days.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.164 which represents an annual dividend yield of 3.51%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.21%
12-Months-Change
Fundamentals
Return on Equity
-6.17%
Trailing 12-Months
Asset Growth
-20.91%
Trailing 12-Months
Company Description
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
Shenzhen Neptunus Interlong Bio-technique Company Limited, together with its subsidiaries, researches, develops, produces, and sells medicines in the People's Republic of China. It is also involved in the purchase, sale, and distribution of medicines and healthcare food products; and research and development of biological technology products. In addition, the company manufactures herbal medicines and generic drugs products, as well as medical devices. The company is based in Shenzhen, the People's Republic of China. Shenzhen Neptunus Interlong Bio-technique Company Limited is a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Earnings & Revenues
Technical Analysis
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
China NT Pharma Group Co., Ltd.
―
Fusen Pharmaceutical Co., Ltd.
―
Huakang Biomedical Holdings Company Limited
―